Translating evidence of HDL and plaque regression

Belinda A. Di Bartolo, Peter J. Psaltis, Christina A. Bursill, Stephen J. Nicholls

Research output: Contribution to journalArticleOtherpeer-review

19 Citations (Scopus)


Considerable evidence from preclinical and population studies suggests that HDLs (high-density lipoproteins) possess atheroprotective properties. Reports from HDL infusion studies in animals and early clinical imaging trials reported evidence of plaque regression. These findings have stimulated further interest in developing new agents targeting HDL. However, the results of more recent imaging studies in the setting of high-intensity statin use have been disappointing. As the concept of plaque changes with HDL therapeutics evolves and imaging technology to evaluate these effects advances, there will become increasing opportunity to determine the effects of HDL agents on atherosclerotic plaque (Graphic Abstract). Visual Overview-An online visual overview is available for this article.

Original languageEnglish
Pages (from-to)1961-1968
Number of pages8
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number9
Publication statusPublished - 1 Jan 2018
Externally publishedYes


  • Animals
  • Atherosclerosis
  • Lipids
  • Research
  • Risk factors

Cite this